Involvement of inflammatory cytokines in obesity and its complications

1. Stepien M, Stepien A, Wlazel RN, Paradowski M, Banach M, Rysz J. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study. Lipids Health Dis. 2014 Feb;13(1):29. DOI: 10.1186/1476-511X-13-2910.1186/1476-511X-13-29392199124507240Open DOISearch in Google Scholar

2. Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA. Obesity and inflammation: epidemiology, risk factors and markers of inflammation. Int J Endocrinol. 2013 Apr;17:1-11. DOI: 10.1155/2013/67815910.1155/2013/678159365216323690772Open DOISearch in Google Scholar

3. Popa S, Moţa M, Popa A, Moţa E, Serafinceanu C, Guja C et al. Prevalence of overweight/obesity, abdominal obesity and metabolic syndrome and atypical cardiometabolic phenotypes in the adult Romanian population: PREDATORR study. J Endocrinol Invest. 2016 Sep;39(9):1045-53. DOI: 10.1007/s40618-016-0470-410.1007/s40618-016-0470-427126310Open DOISearch in Google Scholar

4. Mota M, Popa SG, Mota E, Mitrea A, Catrinoiu D, Cheta DM et al. Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study. J Diabetes. 2016 May;8(3):336-44. DOI: 10.1111/1753-0407.1229710.1111/1753-0407.1229725850521Open DOISearch in Google Scholar

5. Grantham JP, Staub K, Rühli FJ, Henneberg M. Modern diet and metabolic variance-a recipe for disaster? Nutr J. 2014 Feb;13(1):15. DOI: 10.1186/1475-2891-13-1510.1186/1475-2891-13-15392325424502225Open DOISearch in Google Scholar

6. Zeyda M, Huber J, Prager G, Stulnig TM. Inflammation correlates with markers of T-cells subsets including regulatory T cells in adipose tissue from obese patients. Obesity. 2011 Apr;19(4):743–8. DOI: 10.1038/oby.2010.12310.1038/oby.2010.12320508627Search in Google Scholar

7. Marventano S, Kolacz P, Castellano S, Galvano F, Buscemi S, Mistretta A, et al. A review of recent evidence in human studies of n-3 and n-6 PUFA intake on cardiovascular disease, cancer, and depressive disorders: does the ratio really matter?. Int J Food Sci Nutr. 2015 Aug;66(6):611-22. DOI: 10.3109/09637486.2015.107779010.3109/09637486.2015.107779026307560Open DOISearch in Google Scholar

8. Ilich JZ, Kelly OJ, Kim Y, Spicer MT. Low-grade chronic inflammation perpetuated by modern diet as a promoter of obesity and osteoporosis. Arh Hig Rada Toksikol. 2014 Jun;65(2):139-48. DOI: 10.2478/10004-1254-65-2014-254110.2478/10004-1254-65-2014-254124945416Search in Google Scholar

9. Morris MJ, Beilharz JE, Maniam J, Reichelt AC, Westbrook RF. Why is obesity such a problem in the 21st century? The intersection of palatable food, cues and reward pathways, stress, and cognition. Neurosci Biobehav Rev. 2015 Nov;58:36-45. DOI: 10.1016/j.neubiorev.2014.12.00210.1016/j.neubiorev.2014.12.00225496905Open DOISearch in Google Scholar

10. Charo IF, Thaubman MB: Chemokines in the pathogenesis of vascular diseases, Circ Res. 2004;95:858-866. DOI: 10.1161/01.RES.0000146672.10582.1710.1161/01.RES.0000146672.10582.1715514167Search in Google Scholar

11. Lasselin J, Magne E, Beau C, Ledaguenel P, Dexpert S, Aubert A, et al. Adipose Inflammation in Obesity: Relationship With Circulating Levels of Inflammatory Markers and Association With Surgery-Induced Weight Loss. J Clin Endocrinol Metab. 2014 Jan;99(1):E53-61. DOI: 10.1210/jc.2013-267310.1210/jc.2013-267324243638Open DOISearch in Google Scholar

12. Almuraikhy S, Kafienah W, Bashah M, Diboun I, Jaganjac M, Al-Khelaifi F, et al. Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance. Diabetologia. 2016 Nov;59(11):2406–16. DOI: 10.1007/s00125-016-4031-310.1007/s00125-016-4031-3550610227342408Open DOISearch in Google Scholar

13. Orr SF, Kennedy AJ, Hasty AH: Isolation of Adipose Tissue Immune Cells, J Vis Exp. 2013;75:50707. DOI: 10.3791/5070710.3791/50707371822623728515Search in Google Scholar

14. Zarkesh-Esfahani H., Pockley AG, Z. Wu, Hellewell PG, Weetman AP, Ross RJM: Leptin indirectly activates human neutrophils via induction of TNF-α. J Immunol. 2004;172(3):1809–1814. DOI: 10.4049/jimmunol.172.3.180910.4049/jimmunol.172.3.180914734764Open DOISearch in Google Scholar

15. Al-Hamodi Z, Molham AH, Al-Meeri A, Saif-Ali R. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetol Metab Syndr. 2014 Sep;6(1):99. DOI: 10.1186/1758-5996-6-9910.1186/1758-5996-6-99417770725276234Open DOISearch in Google Scholar

16. Pires A, Martins P, Pereira AM, Marinho J, Silva PV, Marques M, et al. Pro-inflammatory triggers in childhood obesity: correlation between leptin, adiponectin and high-sensitivity C-reactive protein in a group of obese Portuguese children. Rev Port Cardiol. 2014 Nov;33(11):691-7. DOI: 10.1016/j.repc.2014.04.00410.1016/j.repc.2014.04.00425448795Open DOISearch in Google Scholar

17. Nascimento H, Coimbra S, Rêgo C, Santos-Silva A, Belo L. Adiponectin, Inflammation and Cardiometabolic Risk Factors in Paediatric Obese Patients: Impact of Interventional Studies, Ed. Gordeladze JO, in Adiposity-Omics and Molecular Understanding, Ed. InTech, Croatia, 2017, 83-111.10.5772/65722Search in Google Scholar

18. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012 Feb;165(3):622-32. DOI: 10.1111/j.1476-5381.2011.01369.x10.1111/j.1476-5381.2011.01369.x331503521545576Open DOISearch in Google Scholar

19. Tan BK, Adya R, Farhatullah S, Lewandowski KC, O’Hare P, Lehnert H. et al.: Omentin-1, a novel adipokine, is decreased in overweight insulin resistant woman with the polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008 Apr;57(4):801-808. DOI: 10.2337/db07-099010.2337/db07-099018174521Open DOISearch in Google Scholar

20. Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N. et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012, 4:37. DOI: 10.1186/1758-5996-4-3710.1186/1758-5996-4-37341149622835063Open DOISearch in Google Scholar

21. Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, et al: Omentin Prevents Myocardial Ischemic Injury Through AMP-Activated Protein Kinase- and Akt-Dependent Mechanisms. J Am Coll Cardiol. 2014 June;63(24):2722-2733. DOI: 10.1016/j.jacc.2014.03.03210.1016/j.jacc.2014.03.03224768874Open DOISearch in Google Scholar

22. Lesná J, Tichá A, Hyšpler R, Musil F, Bláha, Sobotka L. et al. Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction. Nutr Diabetes. 2015 Nov;5(11):e183. DOI: 10.1038/nutd.2015.3310.1038/nutd.2015.33463193526524638Open DOISearch in Google Scholar

23. Dimova R, Tankova T. The Role of Vaspin in the Development of Metabolic and Glucose Tolerance Disorders and Atherosclerosis. Hindawi Publishing Corporation BioMed Res Int. 2015 Apr;1-7.10.1155/2015/823481440246725945347Search in Google Scholar

24. Reaux-Le Goazigo A, Bodineau L, De Mota N, Jeandel L, Chartrel N, Knauf C, et al. Apelin and the proopiomelanocortin system: a new regulatory pathway of hypothalamic alpha-MSH release. Am J Physiol Endocrinol Metab 2011;301:E955–E966. DOI: 10.1152/ajpendo.00090.201110.1152/ajpendo.00090.201121846903Open DOISearch in Google Scholar

25. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1] apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009;54:598–604. DOI: 10.1161/HYPERTENSIONAHA.109.13461910.1161/HYPERTENSIONAHA.109.13461919597036Open DOISearch in Google Scholar

26. Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, Garcia-Almeida J M, Garcia-Arnes J, Tinahones F J, et al. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg 2009;19:1574–1580. DOI: 10.1007/s11695-009-9955-y10.1007/s11695-009-9955-y19756893Open DOISearch in Google Scholar

27. Attane C, Foussal C, Le Gonidec S, Benani A, Daviaud D, Wanecq E et al. Apelin treatment increases complete Fatty Acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice. Diabetes 2012;61:310–320. DOI: 10.2337/db11-010010.2337/db11-0100326641422210322Open DOISearch in Google Scholar

28. Dray C, Knauf C, Daviaud D, Waget A, Boucher J, Buleon M, et al. Apelin stimulates glucose utilization in normal and obese insulinresistant mice. Cell Metab. 2008; 8:437–445. DOI: 10.1016/j.cmet.2008.10.00310.1016/j.cmet.2008.10.00319046574Search in Google Scholar

29. Guvenc Y, Var A, Goker A, Kuscu NK. Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome. J Int Med Res. 2016 Aug; 44(4):796-805. DOI: 10.1177/030006051664542110.1177/0300060516645421553662527225862Open DOISearch in Google Scholar

30. Guzel EC, Celik C, Abali R, Kucukyalcin V, Celik E, Guzel M et al. Omentin and chemerin and their association with obesity in women with polycystic ovary syndrome. Gynecol Endocrinol. 2014 Jun;30(6):419-22. DOI: 10.3109/09513590.2014.88841210.3109/09513590.2014.88841224524360Open DOISearch in Google Scholar

31. Celik MN, Sogut MU. Experimental investigation of the effect on the chemerin adipokine and obesity of pro-biotic use in obese rats, Int J Health Serv. 2017;2(2):58-64.Search in Google Scholar

32. Eisinger K, Bauer S, Schäffler A, Walter R, Neumann E, Buechler C, et al. Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis. Experim Molec Path. 2012 Febr;92(1):90-6.10.1016/j.yexmp.2011.10.00622037282Search in Google Scholar

33. Ganjali S, Sahebkar A, Mahdipour E, Jamialahmadi K, Torabi S, Akhlaghi S et al. Investigation of the Effects of Curcumin on Serum Cytokines in Obese Individuals: A Randomized Controlled Trial. Sci World J. 2014 Febr;1-6.10.1155/2014/898361394234224678280Search in Google Scholar

34. Ciortea R, Mihu D, Mihu CM. Association Between Visceral Fat, IL-8 and Endometrial Cancer. Anticancer Res 2014, 34:379-384.Search in Google Scholar

35. Chan LP, Liu C, Chiang FY, Wang LF, Lee KW, Chen WT, et al. IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCC. Oncotarget, 2017;8(34),56375–56388. DOI: 10.18632/oncotarget.1691410.18632/oncotarget.16914559356828915597Search in Google Scholar

36. Naour N, Rouault C, Fellahi S, Lavoie ME, Poitou C, Keophiphath M et al. Cathepsins in human obesity: changes in energy balance predominantly affect cathep-sins in adipose tissue and in circulation. J Clin Endocrinol Metab. 2010 Apr;95(4):1861-8. DOI: 10.1210/jc.2009-189410.1210/jc.2009-189420164293Search in Google Scholar

37. Brissova M, Aamodt K, Brahmachary P, Prasad N, Hong JY, Dai C, et al. Islet Microenvironment, Modulated by Vascular Endothelial Growth Factor-A Signaling, Promotes β Cell Regeneration. Cell Metab. 2014 March, 19(3):498-511. DOI: 10.1016/j.cmet.2014.02.00110.1016/j.cmet.2014.02.001401285624561261Open DOISearch in Google Scholar

38. Elias I, Franckhauser S and Fatima Bosch. New insights into adipose tissue VEGF-A actions in the control of obesity and insulin resistance. Adipocyte. 2013 Apr;2(2):109–112. DOI: 10.4161/adip.2288010.4161/adip.22880366111223805408Open DOISearch in Google Scholar

39. Daltro PS, Alves PS, Castro MF, Azevedo CM, Vasconcelos JF, Allahdadi KJ, et al. Administration of granulocyte-colony stimulating factor accompanied with a balanced diet improves cardiac function alterations induced by high fat diet in mice. BMC Cardiovasc Disord. 2015 Dec;15:162. DOI: 10.1186/s12872-015-0154-610.1186/s12872-015-0154-6466866726631050Open DOISearch in Google Scholar

40. Lee Y, Song YS, Fang CH, So BI, Park JY, Joo HW et al. Anti-obesity effects of granulocyte-colony stimulating factor in Otsuka-Long-Evans-Tokushima fatty rats. PLoS One. 2014 Aug;9(8):e105603. DOI: 10.1371/journal.pone.010560310.1371/journal.pone.0105603414079825144367Search in Google Scholar

41. Fernandez Alvarez KL, Beldi M, Sarmanho F, Rossetti RAM, Silveira CRF, Mota GR, et al. Local and systemic immunomodulatory mechanisms triggered by Human Papillomavirus transformed cells: a potential role for G-CSF and neutrophils. Nature. 2017 Aug;Scientific Report 7:9002. DOI: 10.1038/s41598-017-09079-310.1038/s41598-017-09079-3556639628827632Open DOISearch in Google Scholar

42. Nov O, Shapiro H, Ovadia H, Tarnovscki T, Dvir I, Shemesh E, et al. Interleukin-1β regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. PLoS ONE. 2013 Jan;8(1):e53626. DOI: 10.1371/journal.pone.005362610.1371/journal.pone.0053626354703023341960Search in Google Scholar

43. Netea MG, Joosten LAB: The NLRP1-IL18 Connection: a stab in the back of obesity-induced inflammation. Cell Metab. 2016 Jan;23(1):6-7. DOI: 10.1016/j.cmet.2015.12.01410.1016/j.cmet.2015.12.01426771112Open DOISearch in Google Scholar

44. Reynolds CM, McGillicuddy FC, Harford KA, Finu-cane OM, Mills KHG, Roche HM. Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells - implications for diet-induced insulin resistance. Mol Nutr Food Res. 2012;56: 1212–1222. DOI: 10.1002/mnfr.20120005810.1002/mnfr.20120005822700321Open DOISearch in Google Scholar

45. Sun Q, Kiernan UA, Shi L, Phillips DA, Kahn BB, Hu FB, et al. Plasma Retinol-Binding Protein 4 (RBP4) Levels and Risk of Coronary Heart Disease: A Prospective Analysis among Women in the Nurses’ Health Study. Circulation. 2013 Apr;113:1-24. DOI: 10.1161/CIRCULATIONAHA.113.00207310.1161/CIRCULATIONAHA.113.002073374165723584360Open DOISearch in Google Scholar

46. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev Immunol. 2011 Feb;11(2):85. DOI: 10.1038/nri292110.1038/nri2921351803121252989Open DOISearch in Google Scholar

47. Moraes-Vieira PM, Yore MM, Dwyer PM, Syed I, Aryal P, Kahn BB. RPB4 Activates Antigen-Presenting Cells, Leading to Adipose Tissue Inflammation and Systemic Insulin Resistance, Cell Metab. 2014 March;19(3):512-526. DOI: 10.1016/j.cmet.2014.01.01810.1016/j.cmet.2014.01.018407800024606904Open DOISearch in Google Scholar

48. Tan HW, Liu X, Bi XP, Xing SS, Li L, Gong HP, et al. IL-18 overexpression promotes vascular inflammation and remodeling in a rat model of metabolic syndrome. Atheroslerosis. 2010, 208:350–357. DOI: 10.1016/j.atherosclerosis.2009.07.05310.1016/j.atherosclerosis.2009.07.05319717152Open DOISearch in Google Scholar

49. Murphy AJ, Kraakman MJ, Kammoun HL, Dragoljevic D, Lee MK, Lawlor KE, et al. IL-18 Production from the NLRP1 Inflammasome Prevents Obesity and Metabolic Syndrome. Cell Metab. 2016 Jan;23(1):155-64. DOI: 10.1016/j.cmet.2015.09.02410.1016/j.cmet.2015.09.02426603191Open DOISearch in Google Scholar

50. Xu X, Wang H, Wang Z, Xiao W. Plasminogen activator inhibitor-1 promotes inflammatory process induced by cigarette smoke extraction or lipopolysaccharides in alveolar epithelial cells. Exp. Lung Res. 2009;35:795–805. DOI: 10.3109/0190214090291251910.3109/0190214090291251919916862Open DOISearch in Google Scholar

51. Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab. 2006;290:961-7. DOI: 10.1152/ajpendo.00506.200510.1152/ajpendo.00506.200516352667Open DOISearch in Google Scholar

52. Kishore P, Li W, Tonelli J, Lee DE, Koppaka S, Zhang K et al. Adipocyte-Derived Factors Potentiate Nutrient-Induced Production of Plasminogen Activator Inhibitor–1 by Macrophages. Sci Trans Med. 2010 Febr;2(20):15-20.10.1126/scitranslmed.300029220371491Search in Google Scholar

53. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol. 2007;67:796–800. DOI: 10.1111/j.1365-2265.2007.02966.x10.1111/j.1365-2265.2007.02966.x17634078Open DOISearch in Google Scholar

54. Jurdana M, Petelin A, Cernelic Bizjak M, Bizjak M, Biolo G, Jenko-Praznikar Z. Increased serum visfatin levels in obesity and its association with anthropometric/biochemical parameters, physical inactivity and nutrition. eSPEN Journal. 2013 Apr;8(2):e59-67. DOI: 10.1016/j.clnme.2013.02.00110.1016/j.clnme.2013.02.001Open DOISearch in Google Scholar

55. Brown JEP, Onyango DJ, Ramanjaneya M, Conner AC, Patel ST. et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic β-cells. J Mol Endocrinol. 2010 March;44:171-178. DOI: 10.1677/JME-09-007110.1677/JME-09-007119906834Open DOISearch in Google Scholar

56. Olszanecka-Gilinanowicz M, Kocelak P, Nylec M, Chudek J, Zahorska-Markiewicz B. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci. 2012 May;8(2):214-218. DOI: 10.5114/aoms.2012.2854710.5114/aoms.2012.28547336103222661992Open DOISearch in Google Scholar

57. Singh M, Benencia F. Inflammatory signals from fat: Visfatin promotes pro-inflammatory activation and leukocyte interaction in endothelial cells. J Immunol. 2017 May;198, Suppl 1:24.Search in Google Scholar

58. Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo M. Angiopoietin-like Protein 2 Promotes Chronic Adipose Tissue Inflammation and Obesity-Related Systemis Insulin Resistance. Cell Metab. 2009 Sept;10(3):178-188. DOI: 10.1016/j.cmet.2009.08.00310.1016/j.cmet.2009.08.00319723494Open DOISearch in Google Scholar

59. Hirasawa M, Takubo K, Osada H, Miyake S, Toda E, Endo M, et al. Angiopoietin-like protein 2 is a multistep regulator of inflammatory neovascularization in a murine model of age-related macular degeneration. J Biol Chem. 2016 Apr;291(14):7373-85. DOI: 10.1074/jbc.M115.71018610.1074/jbc.M115.710186481716926839315Open DOISearch in Google Scholar

60. Nakamura K, Sano S, Fuster JJ, Kikuchi R, Shimizu I, Ohshima K, et al. Secreted frizzled-related protein 5 diminishes cardiac inflammation and protects the heart from ischemia/reperfusion injury. J Biol Chem. 2016 Feb;291(6):2566-75. DOI: 10.1074/jbc.M115.69393710.1074/jbc.M115.693937474272626631720Open DOISearch in Google Scholar

61. Ellabbana A, Abdelhakeemb M, Hamdya M, Fathya I. Impact of obesity on functional and laboratory parameters in patients with rheumatoid arthritis. Egypt Rheumatol Rehabil. 2016 Jan;43(1):21–26. DOI: 10.4103/1110-161X.17742310.4103/1110-161X.177423Open DOISearch in Google Scholar

62. Crowson CS, Matteson EL, Davis JM, Gabriel SE. Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res. 2013 Jan;65(1):71–7. DOI: 10.1002/acr.2166010.1002/acr.21660370739122514156Open DOISearch in Google Scholar

63. Francin PJ, Abot A, Guillaume C, Moulin D, Bianchi A, Gegout-Pottie P, et al. Association between adiponectin and cartilage degradation in human osteoarthritis. Osteoarthritis Cartilage. 2014 Mar 31;22(3):519-26. DOI: 10.1016/j.joca.2014.01.00210.1016/j.joca.2014.01.00224462671Open DOISearch in Google Scholar

64. Koskinen A, Vuolteenaho K, Nieminen R, Moilanen T, Moilanen E. Leptin enhances MMP-l, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. Clin Expr Rheum-Incl Suppl. 2011 Jan 1;29(1):57.10.1016/S1063-4584(10)60038-6Search in Google Scholar

65. Perera PM, Wypasek E, Madhavan S, Rath-Deschner B, Liu J, Nam J, et al. Mechanical signals control SOX-9, VEGF, and c-Myc expression and cell proliferation during inflammation via integrin-linked kinase, B-Raf, and ERK1/2-dependent signaling in articular chondrocytes. Arthritis Res Ther. 2010 May 28;12(3):R106. DOI: 10.1186/ar303910.1186/ar3039291189620509944Open DOISearch in Google Scholar

66. Ungur R, Dronca M, Crăciun EC, Rusu RL, Văleanu M, Onac I, et al. Improvement of total antioxidant status, a possible bioeffect of the ultrasound therapy-a pilot study. Rev Rom Med Lab. 2011;19(2/4):177-183.Search in Google Scholar

67. Hui W, Litherland GJ, Elias MS, Kitson GI, Cawston TE, Rowan AD, et al. Leptin produced by joint white adipose tissue induces cartilage degradation via up-regulation and activation of matrix metalloproteinases. Ann Rheum Dis. 2012 Mar 1;71(3):455-62. DOI: 10.1136/annrheumdis-2011-20037210.1136/annrheumdis-2011-20037222072016Open DOISearch in Google Scholar

68. Kontny E, Zielinska A, Skalska U, Ksiezopolska-Orlowska K, Głuszko P, Maslinski W. Distinct secretory activity and clinical impact of subcutaneous abdominal adipose tissue in women with rheumatoid arthritis and osteoarthritis. Inflammation. 2017 Feb;40(1):106-16. DOI: 10.1007/s10753-016-0459-310.1007/s10753-016-0459-327796618Open DOISearch in Google Scholar

69. Courties A, Sellam J. Osteoarthritis and type 2 diabetes mellitus: What are the links? Diabetes Res Clin Pract. 2016 Dec;122:198-206. DOI: 10.1016/j.diabres.2016.10.02110.1016/j.diabres.2016.10.02127889689Open DOISearch in Google Scholar

70. Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, DeSouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity. 2006;14:2127–2131. DOI: 10.1038/oby.2006.24810.1038/oby.2006.24817189537Open DOISearch in Google Scholar

71. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol 2013 Jan;3(1):1-58. DOI: 10.1002/cphy.c11006210.1002/cphy.c110062412966123720280Open DOISearch in Google Scholar

72. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism. 2008;57:494–501. DOI: 10.1016/j.metabol.2007.11.01010.1016/j.metabol.2007.11.01018328350Open DOISearch in Google Scholar

73. Leach NV, Dronca E, Vesa SC, Sampelean DP, Craciun EC, Lupsor M, et al. Serum homocysteine levels, oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis. Eur J Intern Med. 2014 Oct 31;25(8):762-7. DOI: 10.1016/j.ejim.2014.09.00710.1016/j.ejim.2014.09.00725262992Search in Google Scholar

74. Saieva C, Peluso M, Palli D, Cellai F, Ceroti M, Selvi V, et al. Dietary and lifestyle determinants of malondialdehyde DNA adducts in a representative sample of the Florence City population. Mutagenesis. 2016 Mar;31(4):475-80. DOI: 10.1093/mutage/gew01210.1093/mutage/gew01226961145Open DOISearch in Google Scholar

75. Monickaraj F, Gokulakrishnan K, Prabu P, Sathishkumar C, Anjana RM, Rajkumar JS, et al. Convergence of adipocyte hypertrophy, telomere shortening and hypoadiponectinemia in obese subjects and in patients with type 2 diabetes. Clin Biochem. 2012 Nov 30;45(16):1432-8. DOI: 10.1016/j.clinbiochem.2012.07.09710.1016/j.clinbiochem.2012.07.09722827962Search in Google Scholar

76. Gikas A, Sotiropoulos A, Pastromas V, Papazafiropoulou A, Apostolou O, Pappas S. Seasonal variation in fasting glucose and HbA1c in patients with type 2 diabetes. Prim Care Diab. 2009 May 31;3(2):111-4. DOI: 10.1016/j.pcd.2009.05.00410.1016/j.pcd.2009.05.00419535310Open DOISearch in Google Scholar

77. Csép K. Surrogate Measures of Insulin Resistance in Middle-aged Non-diabetic Subjects. AMM. 2013 Dec;59(6):279-84.10.2478/amma-2013-0064Search in Google Scholar

78. McArdle MA, Finucane OM, Connaughton RM, Mc-Morrow AM, Roche HM. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol. 2013 May;4:52. DOI: 10.3389/fendo.2013.0005210.3389/fendo.2013.00052365062023675368Open DOISearch in Google Scholar

79. Tonding SF., Silva FM., Antonio JP, Azevedo MJ, Canani LHS, Almeida JC. Adiposity markers and risk of coronary heart disease in patients with type 2 diabetes mellitus. Nutr J. 2014 Dec;13(1):124. DOI: 10.1186/1475-2891-13-12410.1186/1475-2891-13-124429282525539716Open DOISearch in Google Scholar

80. Rajendran K, Devarajan N, Ganesan M, Ragunathan M. Obesity, Inflammation and Acute Myocardial Infarction-Expression of leptin, IL-6 and high sensitivity-CRP in Chennai based population. J Thromb. 2012 Aug;10(1):13. DOI: 10.1186/1477-9560-10-1310.1186/1477-9560-10-13344489722891684Open DOISearch in Google Scholar

81. Kleinbongard P, Heusch G, Schulz R: TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther. 2010;127:295-314. DOI: 10.1016/j.pharmthera.2010.05.00210.1016/j.pharmthera.2010.05.00220621692Open DOISearch in Google Scholar

82. Kanda T, Takahashi T, Kudo S, Takeda T, Tsugawa H, et al. Leptin deficiency enhances myocardial necrosis and lethality in a murine model of viral myocarditis. Life Sci. 2004;75:1435-1447.. DOI: 10.1016/j.lfs.2004.03.01210.1016/j.lfs.2004.03.01215240179Open DOISearch in Google Scholar

83. McGaffin KR, Zou B, McTiernan CF, O’Donnell CP: Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res. 2009;83:313-324. DOI: 10.1093/cvr/cvp07110.1093/cvr/cvp071270171819233863Open DOISearch in Google Scholar

84. Liu Q, Yuan B, Lo KA, Patterson HC, Sun Y, Lodish HF. Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. National Acad Sciences. 2012 Sep;109(36):14568-73. DOI: 10.1073/pnas.121161110910.1073/pnas.1211611109343784022904186Open DOISearch in Google Scholar

85. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Rec Commun. 1999;257:79-83. DOI: 10.1006/bbrc.1999.025510.1006/bbrc.1999.025510092513Open DOISearch in Google Scholar

86. Ai M, Otokozawa S, Asztalos BF, White CC, Cupples LA, Nakajima K, at al. Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis. 2011 Aug;217(2):543-8. DOI: 10.1016/j.atherosclerosis.2011.05.03510.1016/j.atherosclerosis.2011.05.035366255721741045Search in Google Scholar

87. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007;115:1408-1416. DOI: 10.1161/CIRCULATIONAHA.106.66694110.1161/CIRCULATIONAHA.106.66694117339545Open DOISearch in Google Scholar

88. Bobbert T, Raila J, Schwarz F, Mai K, Henze A, Pfeiffer AF, Schweigert FJ, Spranger J. Relation between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness. Atherosclerosis. 2010 Dec;213(2):549-51. DOI: 10.1016/j.atherosclerosis.2010.07.06310.1016/j.atherosclerosis.2010.07.06320832065Open DOISearch in Google Scholar

89. Xiao Y, Xu A, Hui X, Zhou P, Li X, Zhong H, et al. Circulating lipocalin-2 and retinol-binding protein 4 are associated with intima-media thickness and subclinical atherosclerosis in patients with type 2 diabetes. PLoS One. 2013 Jun;8(6):e66607. DOI: 10.1371/journal.pone.006660710.1371/journal.pone.0066607368458223799122Search in Google Scholar

90. Horio E, Kadomatsu T, Miyata K, Arai Y, Hosokawa K, Doi Y, et al. Role of Endothelial Cell–Derived Angptl2 in Vascular Inflammation Leading to Endothelial Dys-function and Atherosclerosis Progression Arteriosclerosis. Arterioscler Thromb Vasc Biol. 2014 Apr;34:1-11. DOI: 10.1161/ATVBAHA.113.30311610.1161/ATVBAHA.113.30311624526691Open DOISearch in Google Scholar

91. Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN. Obesity and cardiovascular diseases: implications regarding fitness, fatness and severity in the obesity paradox. J Am Coll Cardiol. 2014 Apr;63(14):1345-54. DOI: 10.1016/j.jacc.2014.01.02210.1016/j.jacc.2014.01.02224530666Open DOISearch in Google Scholar